Live Marvell Technology Vote →

Never Miss Important Company Updates Again

Get AI-powered summaries of SEC filings delivered to your inbox

Follow your favorite stocks and get email alerts when they release important updates. Completely free.

Covers 5,000+ public companies
Get started →
Sign up to stay up to date with the stocks you care about
Follow Q32 Bio Inc.

Get SEC filing alerts via email and in your feed for Q32 Bio Inc.

QTTB

Q32 Bio Inc.

About Q32 Bio Inc.

Q32 Bio Inc. is a biotechnology company developing antibody-based therapeutics targeting immune pathways involved in autoimmune and inflammatory diseases. Its pipeline includes bempikibart, an IL-7Rα antagonist for alopecia areata and atopic dermatitis, and ADX-097, a tissue-targeted complement inhibitor for autoimmune conditions. The company focuses on innovative biologics, leveraging proprietary patents, strategic collaborations, and a clinical-stage model to address unmet medical needs in immune dysregulation.
This description was generated via AI from an annual report. Updated 8 months ago.

Latest SEC Filings from Q32 Bio Inc.

1
1
Q32 Bio Inc. Q32 Bio Reports $7.6 Million Net Loss in Q1 2026, Focuses on Bempikibart Development

Via official filing (AI summary) | about 1 month ago | 0 comments

2
1
Q32 Bio Inc. Q32 Bio Inc. Reports $29.8 Million Net Income and Highlights Bempikibart Program

Via official filing (AI summary) | 3 months ago | 0 comments

3
1
Q32 Bio Inc. Q32 Bio Reports 60% Reduction in Operating Expenses and 58% Improvement in Net Loss for Q3 2025

Via official filing (AI summary) | 7 months ago | 0 comments

4
1
Q32 Bio Inc. Q32 Bio Reports $20.5 Million Net Loss, Decreases Operating Expenses Amid Strategic Restructuring

Via official filing (AI summary) | 10 months ago | 0 comments

5
1
Q32 Bio Inc. Q32 Bio Reports $11 Million Net Loss in Q1 2025 Amid Restructuring and Clinical Focus

Via official filing (AI summary) | about 1 year ago | 0 comments

6
1
Q32 Bio Inc. Q32 Bio Inc. Reports $47.7 Million Net Loss for 2024, Completes Merger with Homology Medicines

Via official filing (AI summary) | about 1 year ago | 0 comments

7
1
Q32 Bio Inc. Q32 Bio Reports Significant Financial Changes Following Merger, Anticipates Continued Losses

Via official filing (AI summary) | over 1 year ago | 0 comments